Company profile
Nexalin Technology, Inc.
NASDAQ: NXL · Healthcare · Medical - Devices
#974 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
34DFH 28DQ 43GM 38SS 26
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, revenue growth (YoY) · ↓ listing tenure, growth stability
Methodology →Revenue TTM
$275.6k
Rev growth YoY (TTM)
+110.3%
Net income (FY)
-$8.2M
Employees
8
as of 2026-08-23
Market cap
$7.3M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$301.6k$301.6k2025
Net income-$8.2M-$8.2M2025
Operating income-$8.4M-$8.4M2025
Total assets$4.6M$4.6M2025
Liabilities$887.3k$887.3k2025
Equity$3.7M$3.7M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Device Sales45%
Equipment30%
Licensing Fee16%
Other9%
By geography
CHINA63%
UNITED STATES37%
The read
What is Nexalin Technology, Inc.’s revenue?
Nexalin Technology, Inc. booked $301.6k in FY2025 revenue, growing 79% year over year — faster than most Healthcare companies we track, at a -2725.8% net margin.
Peers · Healthcare
Atai Beckley Inc.——Kane Biotech Inc.24DCannabis Bioscience International Holdings, Inc.18DBioAtla, Inc.15DABVC BioPharma, Inc.41DTempest Therapeutics, Inc.24DNeighbors
Harris →Key facts
CEOMark White
SectorHealthcare
IndustryMedical - Devices
HeadquartersHouston, TX
ExchangeNASDAQ: NXL
Employees8
IPO date2022-09-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.